2026-06-14T03:37:44Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/202712024-11-28T21:35:19Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Middleton, Mark R author Dalle, Stephane author Claveau, Joel author Mut, Pilar author Hallmeyer, Sigrun author Plantin, Patrice author Highley, Martin author Kotapati, Srividya author Le, Trong Kim author Brokaw, Jane author Abernethy, Amy P 2024-07-09T09:14:04Z 2024-07-09T09:14:04Z 2016-07 Middleton MR, Dalle S, Claveau J, Mut Sanchís P, Hallmeyer S, Plantin P, et al. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Med. 2016 Jul;5(7):1436-43. Epub 2016 Apr 26. 10.1002/cam4.717 2045-7634 Cancer Medicine http://hdl.handle.net/20.500.13003/10282 27118102 L611255066 2-s2.0-84991524888 http://hdl.handle.net/20.500.12105/20271 380048900009 The therapeutic landscape for advanced melanoma has recently been transformed by several novel agents (immune checkpoint inhibitors and molecular-targeted agents). The prospective, multi-site, observational study IMAGE (ipilimumab: management of advanced melanoma in real practice) included a retrospective cohort to describe real-world treatment prior to approval of the immune checkpoint inhibitor ipilimumab. This retrospective cohort of patients, who started second-line/subsequent treatment (index therapy) for advanced melanoma within 3 years before ipilimumab approval, was selected randomly by chart review. Collected data included treatment history, patient outcomes, and healthcare resource utilization. All patients had >= 1 year of follow-up data. This analysis included 177 patients from Europe (69%) and North America (31%). The most common index therapies (used alone or in combination) were fotemustine (23%), dacarbazine (21%), temozolomide (14%), and platinum-based chemotherapy (14%). Most patients (89%) discontinued index treatment during the study period; the most common reason was disease progression (59%). Among patients with tumor assessment (153/177; 86%), 2% had complete response, 5% had partial response, and 12% had stable disease on last tumor assessment. At 1-year study follow-up, median progression-free survival was 2.6 months (95% confidence interval [CI], 2.1-2.9) and median overall survival was 8.8 months (95% CI, 6.5-9.7). During follow-up, 95% of the patients had healthcare visits for advanced melanoma, 74% of whom were hospitalized or admitted to a hospice facility. These results provide insights into patient care with advanced melanoma in the era before ipilimumab and may serve as a benchmark for new agents in future real-world studies. eng Advanced melanoma Ipilimumab Observational study Real-world treatment practice Retrospective Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study research article